Penumbra, Inc. $PEN Shares Acquired by Rhumbline Advisers

Rhumbline Advisers increased its stake in shares of Penumbra, Inc. (NYSE:PEN) by 1.0% in the 2nd quarter, HoldingsChannel reports. The firm owned 110,221 shares of the company’s stock after purchasing an additional 1,074 shares during the period. Rhumbline Advisers’ holdings in Penumbra were worth $28,286,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. AXQ Capital LP acquired a new stake in shares of Penumbra during the 2nd quarter worth about $464,000. Legal & General Group Plc lifted its position in Penumbra by 31.1% during the 2nd quarter. Legal & General Group Plc now owns 83,743 shares of the company’s stock worth $21,491,000 after acquiring an additional 19,851 shares during the period. Magnetar Financial LLC acquired a new stake in shares of Penumbra during the second quarter worth $8,119,000. Dynamic Technology Lab Private Ltd increased its stake in shares of Penumbra by 15.9% during the second quarter. Dynamic Technology Lab Private Ltd now owns 3,360 shares of the company’s stock worth $862,000 after acquiring an additional 460 shares during the period. Finally, 17 Capital Partners LLC raised its stake in shares of Penumbra by 117.7% during the 2nd quarter. 17 Capital Partners LLC now owns 3,856 shares of the company’s stock worth $990,000 after buying an additional 2,085 shares in the last quarter. 88.88% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Penumbra news, Director Harpreet Grewal sold 186 shares of the stock in a transaction that occurred on Tuesday, November 4th. The stock was sold at an average price of $227.58, for a total transaction of $42,329.88. Following the transaction, the director owned 8,516 shares of the company’s stock, valued at $1,938,071.28. This trade represents a 2.14% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Johanna Roberts sold 1,800 shares of the firm’s stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $300.06, for a total value of $540,108.00. Following the transaction, the executive vice president owned 64,736 shares in the company, valued at $19,424,684.16. This trade represents a 2.71% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 35,330 shares of company stock valued at $9,932,319 over the last three months. Company insiders own 4.20% of the company’s stock.

Penumbra Stock Down 0.9%

Shares of Penumbra stock opened at $295.96 on Thursday. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.75 and a quick ratio of 4.04. Penumbra, Inc. has a 1-year low of $221.26 and a 1-year high of $310.00. The business has a 50-day moving average of $258.75 and a 200-day moving average of $257.67. The company has a market capitalization of $11.59 billion, a PE ratio of 78.71, a P/E/G ratio of 2.10 and a beta of 0.51.

Penumbra (NYSE:PEN) last released its earnings results on Wednesday, November 5th. The company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.90 by $0.07. The company had revenue of $354.69 million during the quarter, compared to analysts’ expectations of $340.77 million. Penumbra had a return on equity of 11.55% and a net margin of 11.54%.The business’s revenue was up 17.8% on a year-over-year basis. During the same period in the prior year, the business posted $0.85 EPS. Penumbra has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that Penumbra, Inc. will post 3.67 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts recently commented on the stock. Truist Financial reduced their price objective on shares of Penumbra from $310.00 to $300.00 and set a “buy” rating for the company in a research note on Wednesday, October 15th. JPMorgan Chase & Co. increased their price objective on Penumbra from $265.00 to $275.00 and gave the company a “neutral” rating in a research note on Thursday, November 6th. Royal Bank Of Canada lowered their target price on shares of Penumbra from $330.00 to $325.00 and set an “outperform” rating for the company in a research note on Wednesday, July 30th. Wells Fargo & Company initiated coverage on shares of Penumbra in a report on Tuesday, November 18th. They set an “underweight” rating on the stock. Finally, BTIG Research reiterated a “buy” rating and issued a $320.00 target price on shares of Penumbra in a report on Monday, October 27th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $305.69.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.